CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 150 enrolled
Drug / intervention
Alluzience +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05277337
NCT05277337Phase 4Completed
CompareCT.gov

A Phase IV, Randomized, Interventional, Study to Assess Subject Treatment Session Perception and Investigator Treatment Experience of Alluzience and Vacuum-Dried Botulinum Neurotoxin Type A for Aesthetic Use

Galderma R&D·interventional·Posted Mar 14, 2022·Updated Feb 16, 2024

In Brief

A Phase 4 clinical trial evaluating Alluzience and powder BoNT-A (BOTOX/Vistabel) for Glabellar Frown Lines. Completed, enrolled 150 participants across 8 sites in 2 countries.

Detailed Summary

This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum neurotoxin type A (powder BoNT-A) for treatment of glabellar lines (GL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines
CountriesGermany, United Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedMar 14, 2022
Enrollment StartFeb 4, 2022
Primary CompletionOct 12, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.3 years ago

Interventions

Alluziencebiological

Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection

powder BoNT-A (BOTOX/Vistabel)biological

Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection